PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i> -Mutated Solid Tumors and in Preclinical Models
These findings highlight a novel cooperativity between FGFR2 and p110α that boosts the effectiveness of inavolisib. The data support advancing precision oncology beyond single biomarkers to complex algorithms utilizing co-occurring alterations, suggesting that combining inavolisib with FGFR2 inhibitors may offer enhanced and more durable responses in PIK3CA/FGFR2-altered tumors.
Authors
- Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
- Melissa M. Ronan (ORCID: https://orcid.org/0000-0003-4269-1404)
- Trang Pham (ORCID: https://orcid.org/0009-0000-7464-7323)
- Danilo Maddalo (ORCID: https://orcid.org/0000-0002-3228-1703)
- Zheng Kuang (ORCID: https://orcid.org/0000-0002-8281-677X)
- Sravanthi Cheeti (ORCID: https://orcid.org/0000-0003-2933-6328)
- Marc Hafner (ORCID: https://orcid.org/0000-0003-1337-7598)
- Ethan Sokol (ORCID: https://orcid.org/0000-0002-5480-8473)
- Zachary J. Whitfield (ORCID: https://orcid.org/0000-0001-9965-428X)
- Daniel Zingg (ORCID: https://orcid.org/0000-0001-6450-2534)
- Ian E. Krop (ORCID: https://orcid.org/0000-0002-6380-5944)
- Jennifer L. Schutzman (ORCID: https://orcid.org/0009-0007-3697-5300)
- Andréa Varga (ORCID: https://orcid.org/0000-0002-1314-384X)
- Nicole M. Sodir (ORCID: https://orcid.org/0000-0002-9919-2190)
- Anwesha Dey (ORCID: https://orcid.org/0000-0001-5688-5942)
- Philippe Lucien Bedard (ORCID: https://orcid.org/0000-0002-6771-2999)
- Komal L. Jhaveri (ORCID: https://orcid.org/0000-0003-0472-1254)
- Valentina Gambardella (ORCID: https://orcid.org/0000-0001-6081-8830)
- Jill Fredrickson (ORCID: https://orcid.org/0000-0002-2693-4309)
- Alice R. Wong (ORCID: https://orcid.org/0000-0002-1038-4453)
- Jennifer A. Roth (ORCID: https://orcid.org/0000-0002-5117-5586)
- Mafalda Oliveira (ORCID: https://orcid.org/0000-0001-9152-8799)
- Stephanie Hilz (ORCID: https://orcid.org/0000-0002-6995-6719)
- Kevin Kalinsky (ORCID: https://orcid.org/0000-0002-3113-7902)
- Melissa Accordino (ORCID: https://orcid.org/0000-0002-4156-7279)
- Noopur Shankar (ORCID: https://orcid.org/0009-0005-5698-6782)
- Radia Marie Johnson (ORCID: https://orcid.org/0000-0002-9755-9307)
- Nicholas C. Turner (ORCID: https://orcid.org/0000-0001-8937-0873)
- Peter Schmid (ORCID: https://orcid.org/0000-0001-9817-5228)
- Antoîne Italiano (ORCID: https://orcid.org/0000-0002-8540-5351)
- Ubong Peters (ORCID: https://orcid.org/0000-0002-2491-9519)
- Scott E. Martin (ORCID: https://orcid.org/0000-0001-5685-9787)
- Matthew G. Rees (ORCID: https://orcid.org/0000-0002-2987-7581)
- Robert L. Yauch (ORCID: https://orcid.org/0000-0001-9478-6283)
- Eva Lin (ORCID: https://orcid.org/0009-0001-6099-3847)
- Stephanie Royer‐Joo (ORCID: https://orcid.org/0000-0003-4205-9927)
- Cristina Saura (ORCID: https://orcid.org/0000-0001-8296-5065)
- Steven Gendreau (ORCID: https://orcid.org/0009-0009-4599-7151)
- Dejan Juric (ORCID: https://orcid.org/0000-0003-2983-7704)
- Katherine E. Hutchinson (ORCID: https://orcid.org/0000-0002-4660-3523)
- Jeffrey Lau (ORCID: https://orcid.org/0009-0006-6526-2222)
- Andrés Cervantes (ORCID: https://orcid.org/0000-0003-3806-3691)
- Yanling Jin (ORCID: https://orcid.org/0000-0001-6292-9083)
- Michael S. Hwang (ORCID: https://orcid.org/0009-0004-2146-8558)
- Junko Aimi (ORCID: https://orcid.org/0009-0006-8613-7770)
- Kyung Soon Song (ORCID: https://orcid.org/0009-0003-5464-8814)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Broad Institute (US)
- Hebron University (PS)
- Royal Marsden NHS Foundation Trust (GB)
- University Health Network (CA)
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Sciences Po Bordeaux (FR)
- Emory University (US)
- Université de Bordeaux (FR)
- Queen Mary University of London (GB)
- BioClinica (United States) (US)
- Columbia University Irving Medical Center (US)
- Discovery Centre (CA)
- Institut Gustave Roussy (FR)
- Boston Foundation (US)
- Princess Margaret Cancer Centre (CA)
- Yale Cancer Center (US)
- GlobalFoundries (United States) (US)
- Kettering University (US)
- Massachusetts General Hospital (US)
- Roche (Canada) (CA)
- Gene Therapy Laboratory (FR)
- Hospital Clínico Universitario de Valencia (ES)
- Rancho BioSciences (United States) (US)
- Revolution Medicines (United States) (US)
- Sarah Cannon (US)
- GenØk (NO)
- NeuroDevelopment Center (US)
- Tempus Labs (United States) (US)
- Dana-Farber Cancer Institute (US)
- Royal Marsden Hospital (GB)
- Vietnamese Voluntary Foundation (US)
- Vall d'Hebron Hospital Universitari (ES)
- Institut Bergonié (FR)
- Tennessee Oncology (US)
- Bioinformatics Institute (SG)
- Center for Cancer Research (US)
- INCLIVA Health Research Institute (ES)
- Vall d'Hebron Institute of Oncology (ES)
- Foundation Medicine (United States)
- Sunesis (United States) (US)
- Columbia University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1459
- Citations
- 3
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 2.42